Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 29, 2001
- Drug Cost Ratio Down to 16.8% of Medical Cost for Outpatients in 1998
October 29, 2001
- Olympus Codevelops Ultrasound Surgical System with Intuitive Surgical of the US
October 29, 2001
- Glivec Recommended for Approval
October 29, 2001
- GEYMS Markets Fully-digital Ultrasound Diagnostic Equipment
October 29, 2001
- Dr Takemi, Lawmaker, Strongly Opposes Korosho, MOF Reform Plans
October 29, 2001
- Toshiba, NTT Com to Start ASP Services for Remote Imaging Diagnosis
October 29, 2001
- Korosho's NHI Price System Reform Is Full of Contradictions: Mr Yashiro of FPMAJ
October 29, 2001
- MEDICAL DEVICE NEWS IN BRIEF
October 29, 2001
- Korosho to Control Growth of Medical Spending for Elderly at All Medical Institutions
October 29, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 29, 2001
- METI's Position Paper Calls For Greater Freedom in Healthcare Services
October 29, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 29, 2001
- REGULATORY NEWS IN BRIEF
October 29, 2001
- OTC NEWS IN BRIEF
October 29, 2001
- New Molecular Target-based Therapeutics for Lung Cancer Presented: AstraZeneca Seminar
October 29, 2001
- WORLD NEWS IN BRIEF
October 29, 2001
- Overseas Business Strategy of Domestic Firms Focused on:PMSRL Seminar
October 29, 2001
- Chugai Licenses in Polyglutamate Paclitaxel from CTI Technologies
October 29, 2001
- Meiji Seika to Codevelop Antibiotics with Kosan Biosciences in US
October 29, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…